ReviewThe Journal of infectious diseases2016
Development of Vaccines for Chikungunya Fever.
Review in The Journal of infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.
- Visualized analysis of core themes and emerging frontiers in global chikungunya virus studies.Frontiers in microbiology · 2025Pooled it
- Trial
- Trial
- Chikungunya Vaccines in Travel Medicine: From Regulatory Approval to Real-World Challenges.Tropical medicine and infectious disease · 2026Review
- Mapping Human Clinical Evidence for Chikungunya Vaccines: A Scoping Review of Immunogenicity, Durability, and Safety.Vaccines · 2026Review
- A vaccine candidate based on baculovirus displaying chikungunya virus E1-E2 envelope confers protection against challenge in mice.Journal of virology · 2024Article
- Chikungunya virus vaccine: a decade of progress solving epidemiological dilemma, emerging concepts, and immunological interventions.Frontiers in microbiology · 2024Review
- FHL1 promotes chikungunya and o'nyong-nyong virus infection and pathogenesis with implications for alphavirus vaccine design.Nature communications · 2023Article
- Article
- Integrated control strategies for dengue, Zika, and Chikungunya virus infections.Frontiers in immunology · 2023Review
- Article
- Antigenicity and immunogenicity of chikungunya virus-like particles from mosquito cells.Applied microbiology and biotechnology · 2023Article
- Arboviruses as an unappreciated cause of non-malarial acute febrile illness in the Dschang Health District of western Cameroon.PLoS neglected tropical diseases · 2022Article
- Effectiveness of CHIKV vaccine VLA1553 demonstrated by passive transfer of human sera.JCI insight · 2022Article
- A high-dose inoculum size results in persistent viral infection and arthritis in mice infected with chikungunya virus.PLoS neglected tropical diseases · 2022Article
- Antibody effector analysis of prime versus prime-boost immunizations with a recombinant measles-vectored chikungunya virus vaccine.JCI insight · 2021Article
- Spatial and temporal invasion dynamics of the 2014-2017 Zika and chikungunya epidemics in Colombia.PLoS computational biology · 2021Article
- Non-replicating adenovirus based Mayaro virus vaccine elicits protective immune responses and cross protects against other alphaviruses.PLoS neglected tropical diseases · 2021Article
- Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice.Frontiers in immunology · 2021Article
- Antibody-based therapeutic interventions: possible strategy to counter chikungunya viral infection.Applied microbiology and biotechnology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
Chikungunya fever, an acute and often chronic arthralgic disease caused by the mosquito-borne chikungunya virus (CHIKV), has reemerged since 2004 to cause millions of cases. Because CHIKV exhibits limited antigenic diversity and is not known to be capable of reinfection, a vaccine could serve to both prevent disease and diminish human amplification during epidemic circulation. Here, we review the many promising vaccine platforms and candidates developed for CHIKV since the 1970s, including several in late preclinical or clinical development. We discuss the advantages and limitations of each, as well as the commercial and regulatory challenges to bringing a vaccine to market.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.